The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ZYME · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
SRRK · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
COYA · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | ZYME | SRRK | COYA | STEX |
|---|---|---|---|---|
| Moat Score (0–100) | 35 (highest) | 35 (highest) | 35 (highest) | 35 (highest) |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 54 | 60 (highest) | 40 | 30 |
| Pricing power | — | — | — | 71 |
| Returns on capital | 6 (highest) | 0 | 0 | 0 |
| Balance-sheet safety | 55 (highest) | 55 (highest) | 55 (highest) | 28 |
| Capital discipline | 24 | 24 | 44 (highest) | 44 (highest) |
| Price vs. high estimate | No price data | No price data | No price data | No price data |
| Market cap | $1.8B | $5.5B | $92.9M | $38.7M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |